Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.51 |
| ▸ | RRM2 | P31350 | 1/20 | 0.51 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199380 | 0.81 | ATM (0.48) | ATMMETTL3CTSLCYP1A2 | |
| SCHEMBL2493220 | 0.75 | NCOA3 (0.54) | ATMMETTL3CTSLCYP1A2 | |
| SCHEMBL941093 | 0.75 | TOP2A (0.70) | ATMMETTL3 | |
| SCHEMBL9319994 | 0.75 | TOP2A (0.70) | ATMMETTL3 | |
| SCHEMBL941092 | 0.75 | TOP2A (0.70) | ATMMETTL3 | |
| SCHEMBL4069571 | 0.74 | RRM1 (0.46) | RRM1RRM2RRM2BCISD1CYP1A2 | |
| SCHEMBL28494134 | 0.74 | TOP2A (0.68) | ATMMETTL3 | |
| SCHEMBL28493225 | 0.74 | TOP2A (0.68) | ATMMETTL3 | |
| SCHEMBL3079901 | 0.74 | MAPT (0.51) | ATMMETTL3RRM1RRM2RRM2B | |
| SCHEMBL28454239 | 0.73 | METTL3 (0.44) | ATMMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETADY OF HEALTH AND HUMAN SERVICES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1951230-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007035489-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | DPYD, NTPCR, RRM2B | ATM 366/4885METTL3 1848/4885RRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.